Theravance Biopharma Inc. (TBPH) Downgraded by Robert W. Baird to “Underperform”
Robert W. Baird cut shares of Theravance Biopharma Inc. (NASDAQ:TBPH) from a neutral rating to an underperform rating in a research report report published on Wednesday morning. They currently have $24.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $19.00.
TBPH has been the topic of several other reports. Evercore ISI began coverage on shares of Theravance Biopharma in a research report on Monday, August 29th. They set a buy rating and a $41.00 price objective on the stock. Leerink Swann reissued a buy rating and set a $31.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, August 9th. Guggenheim reissued a positive rating and set a $40.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 19th. Bank of America Corp. downgraded shares of Theravance Biopharma from a neutral rating to an underperform rating in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research upgraded shares of Theravance Biopharma from a hold rating to a buy rating and set a $41.00 price objective for the company in a research note on Tuesday, October 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $35.40.
Theravance Biopharma (NASDAQ:TBPH) traded down 0.365% during mid-day trading on Wednesday, hitting $31.395. 68,830 shares of the stock were exchanged. The company has a 50-day moving average price of $32.99 and a 200-day moving average price of $25.20. The company’s market cap is $1.50 billion. Theravance Biopharma has a one year low of $12.75 and a one year high of $38.92.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative return on equity of 70.79% and a negative net margin of 471.82%. Analysts forecast that Theravance Biopharma will post ($4.03) earnings per share for the current fiscal year.
In other Theravance Biopharma news, SVP Brett K. Haumann sold 9,509 shares of the business’s stock in a transaction on Friday, August 19th. The shares were sold at an average price of $27.97, for a total transaction of $265,966.73. Following the completion of the sale, the senior vice president now owns 197,391 shares in the company, valued at $5,521,026.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Bradford J. Shafer sold 49,122 shares of the business’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the sale, the executive vice president now owns 241,686 shares of the company’s stock, valued at approximately $6,636,697.56. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in TBPH. BNP Paribas Arbitrage SA raised its stake in Theravance Biopharma by 110.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,008 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,577 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,401 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 192 shares during the last quarter. Bellevue Group AG acquired a new stake in Theravance Biopharma during the first quarter valued at $215,000. Finally, Paloma Partners Management Co acquired a new stake in Theravance Biopharma during the second quarter valued at $255,000. Hedge funds and other institutional investors own 69.89% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.